Grant: Engage Grants Program
University of British Columbia
$23,000.00
3D bioprinted cardiac tissue models
FY 2017-18
Summary
During human clinical trials, a large percentage of candidate drugs fail because they are unsafe or ineffective.Even when pre-clinical cell and animal studies seem positive, problems occur because tests done with drugs onthese models are often not predictive of what happens in humans. Much of this is due to significant differencesin biology between species.For instance, ion channels (membrane proteins through which heart cells conduct electrical currents) can varybetween humans and animals. Many drugs, including non-cardiovascular drugs, target these ion channels in theheart, which can potentially result in lethal arrhythmias. Thus, it is critical to use preclinical models that canclosely reproduce what happens in humans to better predict drug safety.To streamline the therapeutic development pipeline, we will develop a novel 3D bioprinted human cardiactissue model which will improve the translational science process for predicting whether drugs will be safe andeffective in humans. The goal is to develop 3D human cardiac tissue structure(s) that closely model theelectrophysiological properties of the human heart, relevant to impulse conduction and arrhythmia generation.We will use a known cardiac cell line, HL-1, that mimics human cardiac cells and and novel microfluidic based3D bioprinting technology and methodologies to build the 3D cardiac tissue. Ultimately, these models areexpected to replace the use of animals to screen drugs for safety and efficacy.To validate our models, we will evaluate the cardiotoxicity potential of a range of known compounds, andcompare the outcome with data obtained using current standard assays. It takes on average over $2.5 billion todevelop and gain marketing approval for a new drug. About $100 million is required to complete thepre-clinical studies alone. Using novel bioprinted models of cardiac tissue is expected to significantly cut thecost and time of bringing a new drug to market.
Program
Engage Grants Program
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
520967-2017
Name nom
Fedida, David
Department département
Anesthesiology, Pharmacology & Therapeutics
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2017
Competition year année de concours
2017
Award amount
23000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
1
Application title
3D bioprinted cardiac tissue models
Keyword
NSERC
Application summary
During human clinical trials, a large percentage of candidate drugs fail because they are unsafe or ineffective.Even when pre-clinical cell and animal studies seem positive, problems occur because tests done with drugs onthese models are often not predictive of what happens in humans. Much of this is due to significant differencesin biology between species.For instance, ion channels (membrane proteins through which heart cells conduct electrical currents) can varybetween humans and animals. Many drugs, including non-cardiovascular drugs, target these ion channels in theheart, which can potentially result in lethal arrhythmias. Thus, it is critical to use preclinical models that canclosely reproduce what happens in humans to better predict drug safety.To streamline the therapeutic development pipeline, we will develop a novel 3D bioprinted human cardiactissue model which will improve the translational science process for predicting whether drugs will be safe andeffective in humans. The goal is to develop 3D human cardiac tissue structure(s) that closely model theelectrophysiological properties of the human heart, relevant to impulse conduction and arrhythmia generation.We will use a known cardiac cell line, HL-1, that mimics human cardiac cells and and novel microfluidic based3D bioprinting technology and methodologies to build the 3D cardiac tissue. Ultimately, these models areexpected to replace the use of animals to screen drugs for safety and efficacy.To validate our models, we will evaluate the cardiotoxicity potential of a range of known compounds, andcompare the outcome with data obtained using current standard assays. It takes on average over $2.5 billion todevelop and gain marketing approval for a new drug. About $100 million is required to complete thepre-clinical studies alone. Using novel bioprinted models of cardiac tissue is expected to significantly cut thecost and time of bringing a new drug to market.